Skip to main content
. 2019 Apr;189(4):797–812. doi: 10.1016/j.ajpath.2018.12.016

Figure 11.

Figure 11

Effect of inhibition of NF-κB pathway and transforming growth factor-β–activating kinase (TAK)-1 on lipopolysaccharide (LPS)-induced activation of myosin light chain kinase (MLCK) expression in mouse enterocytes. A: NF-κB inhibitor ammonium pyrrolidinedithiocarbamate (PDTC) prevented LPS-induced increase in MLCK protein expression (5 day) compared with vehicle- or LPS-treated mice. Densitometry of MLCK protein levels. B: NF-κB inhibitor Bay-11 also prevented LPS-induced increase in MLCK protein expression (5 day) compared with vehicle- or /LPS-treated mice. Densitometry of MLCK protein levels. C: Pretreatment with TAK-1 inhibitor (in; inh), oxyzeanol (Oxz; 5 mg/kg body weight), prevented the LPS-induced increase in MLCK protein expression (5 day) compared with vehicle- or LPS-treated mice. Densitometry of MLCK protein levels. n = 3 experiments. ∗∗P < 0.01 versus control; ††P < 0.01 versus LPS. C, control.